← 產業報告目錄
Biosimilar Monoclonal Antibodies Market Size, Share & Trends Analysis Report By Product (Infliximab, Trastuzumab, Rituximab, Adalimumab, Bevacizumab, Cetuximab, Ranibizumab, Denosumab, Eculizumab, Other Pipeline Products), By Indication, By Region, And Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-03-03頁數 180報告編號 INSIGHTACE-06950fdfc5
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The Biosimilar Monoclonal Antibodies Market on a global scale was estimated at USD 7.8 Billion in 2024 and is projected to attain USD 32.1 Billion by 2034, with a projected CAGR of 15.3% between 2025 and 2034.
Biosimilar Monoclonal Antibodies encompasses key industry insights & findings from the report:
The rising occurence of chronic diseases like cancer, autoimmune disorders, and inflammatory diseases is driving the biosimilar monoclonal antibodies. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
The market's upward path is supported by rising healthcare spending, technological evolution, and the rising focus on personalized and precision-based approaches in healthcare.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
From a regional perspective, mature markets in North America and Europe continue to hold substantial shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and rising investment in the sector.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Biosimilar Monoclonal Antibodies Market Snapshot
Chapter 4. Global Biosimilar Monoclonal Antibodies Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Clinical Trial/Pipeline Analysis
4.9. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 2: By Products Estimates & Trend Analysis
5.1. By Products & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:
5.2.1. Infliximab
5.2.2. Trastuzumab
5.2.3. Rituximab
5.2.4. Adalimumab
5.2.5. Bevacizumab
5.2.6. Ranibizumab
5.2.7. Denosumab
5.2.8. Eculizumab
5.2.9. Filgrastim
5.2.10. Pegfilgrastim
5.2.11. Ustekinumab
5.2.12. Other Pipeline drugs
Chapter 6. Market Segmentation 4: By Indications Estimates & Trend Analysis
6.1. By Indications & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Indications:
6.2.1. Autoimmune Diseases
6.2.2. Oncology
6.2.3. Ophthalmic Disorders
6.2.4. Bone Disorders
6.2.5. Rare Hematologic/Neurologic Disorders
6.2.6. Hematologic Support
6.2.7. Inflammatory Bowel Disease
6.2.8. Other Indication
Chapter 7. Biosimilar Monoclonal Antibodies Market Segmentation 5: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts By Products, 2021-2034
7.1.2. North America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts By Types, 2021-2034
7.1.3. North America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indications, 2021-2034
7.1.4. North America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.2. Europe
7.2.1. Europe Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Products, 2021-2034
7.2.2. Europe Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Types, 2021-2034
7.2.3. Europe Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indications, 2021-2034
7.2.4. Europe Biosimilar Monoclonal Antibodies Market revenue (US$ Million) by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Products, 2021-2034
7.3.2. Asia Pacific Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Types, 2021-2034
7.3.3. Asia Pacific Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indications, 2021-2034
7.3.4. Asia Pacific Biosimilar Monoclonal Antibodies Market revenue (US$ Million) by country, 2021-2034
7.4. Latin America
7.4.1. Latin America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Products, 2021-2034
7.4.2. Latin America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Types, 2021-2034
7.4.3. Latin America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indications, 2021-2034
7.4.4. Latin America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) by country, 2021-2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Products, 2021-2034
7.5.2. Middle East & Africa Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Types, 2021-2034
7.5.3. Middle East & Africa Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indications, 2021-2034
7.5.4. Middle East & Africa Biosimilar Monoclonal Antibodies Market revenue (US$ Million) by country, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Accord BioPharma Inc.
8.2.2. Alvotech USA Inc.
8.2.3. Amgen Inc.
8.2.4. Amneal Pharmaceuticals LLC
8.2.5. Biocon Biologics Inc.
8.2.6. Biogen Netherlands B.V.
8.2.7. Biosimilar Collaborations Ireland Limited
8.2.8. Bio-Thera Solutions, Ltd.
8.2.9. Boehringer Ingelheim Pharmaceuticals, Inc.
8.2.10. Celltrion Healthcare Hungary Kft.
8.2.11. Coherus BioSciences, Inc.
8.2.12. CuraTeQ Biologics s.r.o
8.2.13. Eli Lilly and Company
8.2.14. FGK Representative Service GmbH
8.2.15. Formycon AG
8.2.16. Fresenius Kabi
8.2.17. Gedeon Richter Plc.
8.2.18. Hexal AG
8.2.19. Hong Kong King-Friend Industrial Company Limited
8.2.20. Hospira Inc., a Pfizer Company
8.2.21. Juta Pharma GmbH
8.2.22. Kashiv BioSciences, LLC
8.2.23. Mabxience Research SL
8.2.24. Medice Arzneimittel Pütter GmbH Co. KG
8.2.25. Midas Pharma GmbH
8.2.26. Mundipharma Corporation (Ireland) Limited
8.2.27. Pfizer Inc.
8.2.28. Qilu Pharma Spain S.L.
8.2.29. Ratiopharm GmbH
8.2.30. Reddy Holding GmbH
8.2.31. Samsung Bioepis Co., Ltd.
8.2.32. Sandoz Inc.
8.2.33. Sanofi
8.2.34. Stada Arzneimittel AG
8.2.35. Strides Pharma (Cyprus) Limited
8.2.36. Tanvex BioPharma USA, Inc.
8.2.37. Techdow Pharma Netherlands B.V.
8.2.38. Teva GmbH
8.2.39. Theramex Ireland Limited
8.2.40. Other prominent players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們